Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction
Brief Summary
Serotonin and oxytocin play a role in fear conditioning and fear extinction learning, psychological processes that are critically involved in psychiatric disorders such as posttraumatic stress disorder (PTSD). Specifically, administration of oxytocin has been shown to facilitate fear extinction in humans. Similarly, substances that release serotonin and oxytocin such as MDMA have been shown to enhance the extinction of fear memory in animals. However, there are no data on the effects of MDMA on fear extinction in humans. Therefore, the primary aim of this study is to investigate the role of acute serotonin release in the effects of fear extinction. MDMA will be used as pharmacological tool to induce serotonin release in this study.
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Completed |
| Study results: | No Results Available |
| Age: | 18 Years to 50 Years (Adult) |
| Enrollment: | 30 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Oct 18, 2019 | |
|---|---|---|
| Primary Completion: | Dec 10, 2020 | |
| Completion Date: | Dec 24, 2020 | |
| Study First Posted: | May 17, 2018 | |
| Results First Posted: | Aug 30, 2020 | |
| Last Updated: | Jan 19, 2022 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Eligibility Criteria
| Sex: | Male |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 50 |
More Details
| NCT Number: | NCT03527316 |
|---|---|
| Acronym: | MFE |
| Other IDs: | BASEC 2017-01947 |
| Study URL: | https://ClinicalTrials.gov/show/NCT03527316 |
Last updated: Jun 16, 2022